MedTrace Logo

First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors

NCT01323933 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2012-05-03

No results posted yet for this study

Summary

Analysis of safety, tolerability, and PK data will provide information that will guide future development of AB0024.

Conditions

  • Neoplasms

Interventions

DRUG

AB0024

Comparison of different dosages of drug

Sponsors & Collaborators

Principal Investigators

  • Patricia LoRusso, DO · Barbara Ann Karmanos Cancer Institute

  • Anthony Tolcher, MD · South Texas Accelerated Research Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01323933 on ClinicalTrials.gov